Cell based signal generation

• US 7,022,513 B2
• Filed: 07/18/2002
• Issued: 04/04/2006
• Est. Priority Date: 02/01/1999
• Status: Active Grant

• Current Assignee: Cadus Technologies Incorporated
• Original Assignee: Cadus Technologies Incorporated
• Inventors: Trueheart, Joshua, Xu, Jun
• Primary Examiner(s): Ketter, James
• Assistant Examiner(s): Lambertson, David A.
• Application Number:
  US10/200,013
• Publication Number:
  US 20030170760A1
• Time in Patent Office: 1,356 Days
• Field of Search: 435/243, 435/254.1, 435/254.11, 435/254.2, 435/254.21, 435/255.1, 435/255.2
• US Class Current: 435/255.1
• CPC Class Codes: C07K 14/39 from yeasts
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

The present invention makes available a rapid, reproducible, robust assay system for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular protein, e.g., a receptor or ion channel. The subject assay enables rapid screening of large numbers of compounds to identify those which act as an agonist or antagonist to the bioactivity of the cellular protein. In particular, the assay of the invention makes use of a cell that harbors a protein that is responsive to a cellular signal transduction pathway. The protein is operatively linked to a polypeptide which causes a detectable signal to be generated upon stimulation of the pathway, e.g., when a compound interacts with and modulates the activity of a cellular receptor or ion channel of the cell. Thus, the cell provides a signal generation means comprising a novel fusion protein the expression of which is independent of stimulation/activation of the signal transduction pathway, but the activity of which is responsive to the signal transduction pathway.

Claims

1. A recombinant yeast cell comprising:

a mutated Fus3 yeast protein comprising an amino acid substitution at positions 42, 180 or 182, or at positions 180 and 182 as compared to wild type Fus3, and wherein said yeast protein is operatively linked to a chimeric transcription factor;

a heterologous receptor selected from the group consisting of melatonin receptor 1a, galanin receptor 1, neurotensin receptor, adenosine receptor 2a, somatostatin receptor 2, and corticotropin releasing factor receptor 1, wherein said receptor is functionally integrated into a pheromone response pathway of the yeast cell; and

a gene which produces a detectable protein, wherein said yeast protein is responsive to said yeast pheromone response pathway of the cell; and

wherein the activity of said yeast protein is modulated indirectly upon stimulation of said pathway, and wherein upon modulation of said yeast protein, said chimeric transcription factor causes a detectable signal to be generated.

2. The recombinant yeast cell of claim 1, wherein said gene is an endogenous gene at its natural location in the yeast cell.

3. The recombinant yeast cell of claim 1, wherein said mutated Fus3 yeast protein is derived from said wild type Fus3 yeast protein.

4. The recombinant yeast cell of claim 1, wherein said transcription factor is selected from the group consisting of bacterial, viral and eukaryotic transcription factors.

5. The recombinant yeast cell of claim 1, wherein said chimeric transcription factor comprises a protein selected from the group consisting of Ade1, Ade2, Ade3, Ade4, Ade5, Ade7, Ade8, Asp3, Arg1, Arg3, Arg4, Arg5, Arg6, Arg8, Aro2, Aro7, Bar1, CAT, Cho1, Cys3, Gal1, Gal7, Gal10, GFP, His1, His3, His4, His5, Hom3, Hom6, Ilv1, Ilv2, Ilv5, Ino1, Ino2, Ino4, lacZ, Leu1, Leu2, Leu4, luciferase, Lys2, Mal, Mel, Met2, Met3, Met4, Met8, Met9, Met14, Met16, Met19, Ole1, Pho5, Pro1, Pro3, Thr1, Thr4, Trp1, Trp2, Trp3, Trp4, Trp5, Ura1, Ura2, Ura3, Ura4, Ura5, Ura10, Cdc25, Cyr1 and Ras, or fragment thereof.

6. The recombinant yeast cell of claim 1, wherein said heterologous receptor is melatonin receptor 1a.

7. The recombinant yeast cell of claim 1, wherein said chimeric transcription factor comprises an enzyme.

8. The recombinant yeast cell of claim 7, wherein said enzyme is selected from the group consisting of CAT, Gal1, lacZ, Mel, and Pho5.

9. The recombinant yeast cell of claim 1, wherein said chimeric transcription factor comprises a protein required for cell viability.

10. The recombinant yeast cell of claim 9, wherein said protein required for cell viability is selected from the group consisting of Gal1, His3, Leu2, Mel, Ura3, Cdc25, Cyr1 and Ras.

11. The recombinant yeast cell of claim 1, wherein said transcription factor comprises an indicator molecule.

12. The recombinant yeast cell of claim 11, wherein said indicator molecule is GFP.

13. The recombinant yeast cell of claim 1 further comprising a promoter operatively linked to said gene, such that upon modulation of the activity of said yeast protein, the activity of said chimeric transcription factor is stimulated, thereby activating transcription of said gene that produces said detectable protein.

14. The recombinant yeast cell of claim 13, wherein said promoter comprises the minimal Gal promoter and LexA operators, said gene is lacZ, and said detectable protein is β

-galactosidase.

15. The recombinant yeast cell of claim 1, wherein the activity of said mutated Fus3 yeast protein is modulated by wild type Fus3, and wherein the activity of said wild type Fus3 is directly modulated upon stimulation of said pheromone response pathway.

16. The recombinant yeast cell of claim 15, wherein said chimeric transcription factor comprises a LexA DNA binding domain operatively linked to a B42 transcriptional activation domain.

17. The recombinant yeast cell of claim 15, wherein said chimeric transcription factor comprises a Gal4 DNA binding domain operatively linked to a B42 transcriptional activation domain.

18. The recombinant yeast cell of claim 15, wherein said chimeric transcription factor comprises a Gal4 DNA binding domain operatively linked to a VP16 transcriptional activation domain.

19. The recombinant yeast cell of claim 15, wherein said chimeric transcription factor comprises a Gal4 DNA binding domain operatively linked to a Gal4 transcriptional activation domain II.

20. The recombinant yeast cell of claim 1, wherein said transcription factor is a yeast transcription factor.

21. The recombinant yeast cell of claim 20, wherein said transcription factor is selected from the group consisting of Ste12, Gal4, Pho4, Gcn4, Hap1, Adr1, Ace2, Cup2, Swi5 and Bas1.

22. The recombinant yeast cell of claim 21, wherein said transcription factor is Ste12.

23. The recombinant yeast cell of claim 21, wherein said transcription factor is Gal4.

24. The recombinant yeast cell of claim 21, wherein said transcription factor is Pho4.

25. The recombinant yeast cell of claim 1, wherein said chimeric transcription factor comprises a DNA binding domain operatively linked to a transcriptional activation domain.

26. The recombinant yeast cell of claim 25, wherein said DNA binding domain comprises a polypeptide sequence derived from a polypeptide selected from the group consisting of LexA, Gal4, Adr1, Ace2, Cup2, Bas1, Gcn4, Swi5, Pho4, Hap1 and LacI, and wherein said transcriptional activation domain comprises a polypeptide sequence derived from a polypeptide selected from the group consisting of B42, Gal4, Adr1, Ace2, Cup2, Bas1, Gcn4, Swi5, Pho4, Hap1, VP16, and Ste12.

27. The recombinant yeast cell of claim 26, wherein said DNA binding domain comprises a polypeptide sequence derived from LexA.

28. The recombinant yeast cell of claim 26, wherein said DNA binding domain comprises a polypeptide sequence derived from Gal4.

29. The recombinant yeast cell of claim 26, wherein said DNA binding domain comprises a polypeptide sequence derived from Pho4.

30. The recombinant yeast cell of claim 26, wherein said transcriptional activation domain comprises a polypeptide sequence derived from B42.

31. The recombinant yeast cell of claim 26, wherein said transcriptional activation domain comprises a polypeptide sequence derived from VP16.

32. The recombinant yeast cell of claim 26, wherein said transcriptional activation domain comprises a polypeptide sequence derived from Gal4.

33. The recombinant yeast cell of claim 26, wherein said transcriptional activation domain comprises a polypeptide sequence derived from Ste12.

34. The recombinant yeast cell of claim 25, wherein said DNA binding domain and transcriptional activation domain are derived from the same protein.

35. The recombinant yeast cell of claim 34, wherein said chimeric transcription factor comprises a Gal4 DNA binding domain operatively linked to a Gal4 transcriptional activation domain II.

36. The recombinant yeast cell of claim 25, wherein said DNA binding domain and transcriptional activation domain are derived from different proteins.

37. The recombinant yeast cell of claim 36, wherein said chimeric transcription factor comprises a LexA DNA binding domain operatively linked to a B42 transcriptional activation domain.

38. The recombinant yeast cell of claim 36, wherein said chimeric transcription factor comprises a Gal4 DNA binding domain operatively linked to a B42 transcriptional activation domain.

39. The recombinant yeast cell of claim 36, wherein said chimeric transcription factor comprises a Gal4 DNA binding domain operatively linked to a VP16 transcriptional activation domain.

40. The recombinant yeast cell of claim 1, wherein said heterologous receptor is expressed in the membrane of said yeast cell.

41. The recombinant yeast cell of claim 40, further comprising a heterologous test polypeptide, wherein said heterologous test polypeptide is transported to a location allowing interaction with the extracellular region of said heterologous receptor, and wherein said heterologous test polypeptide is expressed at a sufficient level such that modulation of the signal transduction activity of the receptor by the heterologous test polypeptide alters said detectable signal.

42. The recombinant yeast cell of claim 41, wherein said heterologous test polypeptide includes a signal sequence that facilitates transport of the polypeptide to a location allowing interaction with the extracellular region of the receptor.

43. The recombinant yeast cell of claim 1, further comprising a promoter, wherein transcription of said gene is controlled by said promoter.

44. The recombinant yeast cell of claim 43, wherein said promoter is selected from the group consisting of Gal1, Gal10, Mel and LexA operator.

45. The recombinant yeast cell of claim 43, wherein upon modulation of the activity of said yeast protein, said yeast protein activates transcription of said gene that produces said detectable protein.

46. The recombinant yeast cell of claim 45, wherein said detectable protein is selected from the group consisting of α

-galactosidase, β

-galactosidase, alkaline phosphatase, horseradish peroxidase, exoglucanase, luciferase, Bar1, Pho5 acid phosphatase, green fluorescent protein, chitinase, and chloramphenicol acetyl transferase.

47. The recombinant yeast cell of claim 45, wherein said gene is selected from the group consisting of ADE1, ADE2, ADE3, ADE4, ADE5, ADE7, ADE8, ASP3, ARG1, ARG3, ARG4, ARG5, ARG6, ARG8, ARO2, ARO7, BAR1, CAT, CHO1, CYS3, GAL1, GAL7, GAL10, GFP, HIS1, HIS3, HIS4, HIS5, HOM3, HOM6, ILV1, ILV2, ILV5, INO1, INO2, INO4, lacZ, LEU1, LEU2, LEU4, luciferase, LYS2, MAL, MEL, MET2, MET3, MET4, MET8, MET9, MET14, MET16, MET19, OLE1, PHO5, PRO1, PRO3, THR1, THR4, TRP1, TRP2, TRP3, TRP4, TRP5, URA1, URA2, URA3, URA4, URA5 and URA10.

48. The recombinant yeast cell of claim 47, wherein said gene is selected from the group consisting of CAT, GAL1, GAL7, GAL10, GFP, HIS3, lacZ, luciferase, LEU2, MEL, PHO5, and URA3.

49. A recombinant yeast cell comprising:

a mutated Fus3 yeast protein comprising an amino acid substitution at positions 42, 180 or 182, or at positions 180 and 182 as compared to wild type Fus3, wherein said amino acid substitution is selected from the group consisting of Lys42Arg, Thr180Val, Thr180Glu, Tyr182Val and Tyr182Asp and wherein said yeast protein is operatively linked to a chimeric transcription factor;

a heterologous receptor selected from the group consisting of melatonin receptor 1a, galanin receptor 1, neurotensin receptor, adenosine receptor 2a, somatostatin receptor 2, and corticotropin releasing factor receptor 1, wherein said receptor is functionally integrated into a pheromone response pathway of the yeast cell; and

a gene which produces a detectable protein, wherein said yeast protein is responsive to said yeast pheromone response pathway of the cell; and

wherein the activity of said yeast protein is modulated indirectly upon stimulation of said pathway, and wherein upon modulation of said yeast protein, said chimeric transcription factor causes a detectable signal to be generated.